Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT01615029Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2012
- Primary completion
- Oct 2015
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Jun 2012; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01615029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01615029.